The endocrinologist calls the recording a proud career moment and asks followers to set aside an hour for the class. The topic isn't stated.
Recap by typeshit. Post by @drsalaswhalen on Instagram.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
An explainer on how oral peptide drugs are designed to survive the gut and still reach specific targets in the body. Little detail beyond the title.
Pooling four studies with confirmed first-trimester exposure, researchers found an odds ratio of 0.99 for major malformations, though they flag confounding and comparator limits.
Loading…